Previous 10 |
At Phase 3 of development, expecting to have $55 million in cash after the sale of warrants and with very little debt, BioLineRx (BLRX) is interesting. In addition, the company trades with an enterprise value of only $12 million, which seems very small. Other competitors at a similar stage of ...
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the opportunity investors have in front of them is BioRestorative Therapies, Inc. (BRTX) , ...
TEL AVIV, Israel , Feb. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), eac...
BioLineRx (NASDAQ: BLRX ) has commenced public offering of American Depositary Shares (ADSs), each representing one ordinary share with ADS to be sold together in a fixed combination with a warrant to purchase ADSs. More news on: BioLineRx Ltd., Healthcare stocks news, Read more ... ...
BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants Canada NewsWire TEL AVIV, Israel, Feb. 4, 2019 TEL AVIV, Israel , Feb. 4, 2019 /CNW/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical com...
CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The healthcare stock market has garnered copies amounts of media attention over the course of the past few years, as more people have come to understand the variety of benefits of introducing cannabis as a means of treatment for a myriad o...
The FDA has granted Orphan Drug Designation (ODD) to BioLineRx's (NASDAQ: BLRX ) lead oncology candidate, BL-8040, for the treatment of pancreatic cancer. More news on: BioLineRx Ltd., Bioline RX Ltd., Healthcare stocks news, Stocks on the move, Read more ...
TEL AVIV, Israel , Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology candid...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...